Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00622505 · ClinicalTrials.gov registry record · Phase 4
Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
A Phase 4 study of Multiple Myeloma, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 121
- Enrollment target
- 20
- Study locations
NCT00622505 is a Phase 4 study of Multiple Myeloma that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 121 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT00622505, a Phase 4 study of Multiple Myeloma, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 121 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluated the effectiveness and safety of a dosing method for zoledronic acid in preventing skeletal complications in multiple myeloma participants who have been on an intravenous (IV) bisphosphonate for about one to two years.
Conditions Studied
Interventions
- DRUG zoledronic acid
Study Locations (20)
California
- Wilshire Oncology Medical Group - La Verne
- Cedars Sinai Medical Center Outpatient Cancer Ctr. (4) - Los Angeles
- Palo Alto Medical Foundation Hematology/Oncology - Mountain View
- Oncology Care Medical Associates - San Gabriel
- Santa Clara Valley Health & Hospital System - San Jose
Florida
- Palm Beach Institute of Hematology Oncology - Boynton Beach
- Innovative Medical Research of South Florida Innovative Med Research - Miami Shores
- Cancer Centers of Florida PA Cancer Centers of Central FL - Ocoee
- Integrated Community Oncology Network Florida Oncology Associates - Orange Park
- Cleveland Clinic Florida - Weston
Maryland
- University of Maryland Greenebaum Cancer Center - Baltimore
- Center for Cancer & Blood Disorders - Bethesda
- Oncology - Hematology Associates, PA Oncology Hematology Assoc - Clinton
Massachusetts
- Dana Farber Cancer Institute Clinical Research Coordinator - Boston
- Boston VA Healthcare Boston VA - Boston
Arizona
- TriValley Cancer Research and Treatment Center - Casa Grande
Colorado
- University of Colorado U of Colorado Cancer Center - Aurora
Connecticut
- Hematology Oncology PC - Stamford
District of Columbia
- Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2007-11-07 |
| Est. Completion | 2012-04-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00622505
The ClinicalTrials.gov registry entry for NCT00622505 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (78% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which zoledronic acid is the first listed.
NCT00622505 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT00622505 about?
NCT00622505 is a clinical study titled "Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants". This study evaluated the effectiveness and safety of a dosing method for zoledronic acid in preventing skeletal complications in multiple myeloma participants who have been on an intravenous (IV) bisphosphonate for about one to two years.
What is the current status of trial NCT00622505?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 121 participants. The study started on 2007-11-07. Estimated completion is 2012-04-03.
What conditions does trial NCT00622505 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00622505?
The interventions under investigation include: zoledronic acid (DRUG).
Who is sponsoring clinical trial NCT00622505?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00622505 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
RECRUITING · Phase 4
-
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RECRUITING · Phase 4
-
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
RECRUITING · Phase 4
-
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
ACTIVE NOT RECRUITING · Phase 4
-
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
COMPLETED · Phase 4
-
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.